Paper
N-Alkylated arylsulfonamides of (aryloxy)ethyl piperidines: 5-HT(7) receptor selectivity versus multireceptor profile.
Published Jan 15, 2016 · V. Canale, Rafał Kurczab, A. Partyka
Bioorganic & medicinal chemistry
Q2 SJR score
16
Citations
1
Influential Citations
Abstract
Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.
Non-RCT
Animal StudyStudy Snapshot
N-alkylated arylsulfonamides show potential as selective 5-HT7 receptor ligands or multifunctional agents for treating complex CNS disorders.
PopulationOlder adults (50-71 years)
Sample size24
MethodsObservational
OutcomesBody Mass Index projections
ResultsSocial networks mitigate obesity in older groups.
Sign up to use Study Snapshot
Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.
Full text analysis coming soon...
References
Arylsulfonamide derivatives of (aryloxy)ethylpiperidines as selective 5-HT7 receptor antagonists and their psychotropic properties
Arylsulfonamide derivatives of (aryloxy)ethylpiperidines show potential as antidepressant, anxiolytic, and pro-cognitive treatments for CNS disorders.
2015·13citations·P. Zajdel et al.·MedChemComm
MedChemComm
Towards novel 5-HT7versus 5-HT1A receptor ligands among LCAPs with cyclic amino acid amide fragments: design, synthesis, and antidepressant properties. Part II.
Novel long-chain arylpiperazines with cyclic amino acid amide fragments show potential as antidepressant-like drugs by binding to 5-HT7 and 5-HT1A receptors.
2015·14citations·V. Canale et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date
Targeting the serotonin 5-HT7 receptor may offer potential treatments for mood disorders, learning and memory issues, schizophrenia, epilepsy, migraine, autism spectrum disorders, and Rett Syndrome.
2015·108citations·A. Nikiforuk·CNS Drugs
CNS Drugs
Inhibition of Insulin-Regulated Aminopeptidase (IRAP) by Arylsulfonamides
Arylsulfonamides show moderate inhibitory potency against insulin-regulated aminopeptidase (IRAP), with potential as research tools and cognitive enhancers.
2014·26citations·Sanjay R. Borhade et al.·ChemistryOpen
ChemistryOpen
3-Substituted-N-(4-Hydroxynaphthalen-1-yl)arylsulfonamides as a Novel Class of Selective Mcl-1 Inhibitors: Structure-Based Design, Synthesis, SAR, and Biological Evaluation
Compound 21, a selective Mcl-1 inhibitor, effectively kills cancer cells by disrupting the protein's interaction with other proteins, making it a promising cancer therapy.
2014·70citations·Fardokht A. Abulwerdi et al.·Journal of Medicinal Chemistry
Journal of Medicinal Chemistry
Citations
The 5-HT7 receptor system as a treatment target for mood and anxiety disorders: A systematic review
The 5-HT7 receptor system shows potential as a treatment target for mood and anxiety disorders, but further research is needed using drugs that specifically bind to this receptor.
2023·8citations·Natalie Gottlieb et al.·Journal of Psychopharmacology (Oxford, England)
Journal of Psychopharmacology (Oxford, England)
Development and challenges in the discovery of 5-HT1A and 5-HT7 receptor ligands.
Serotonin receptors 5-HT1A and 5-HT7 are crucial for mood regulation, sleep, and appetite, but their functional interaction remains unidentified.
2022·7citations·Deepika Singh et al.·Bioorganic chemistry
Bioorganic chemistry
New, Eco-Friendly Method for Synthesis of 3-Chlorophenyl and 1,1′-Biphenyl Piperazinylhexyl Trazodone Analogues with Dual 5-HT1A/5-HT7 Affinity and Its Antidepressant-like Activity
The new microwave-assisted method efficiently synthesizes 5-HT1A/5-HT7 receptor ligands with strong and specific antidepressant-like activity, offering potential for future depression treatments.
2022·2citations·Przemysław Zaręba et al.·Molecules
Molecules
Multi-targeted drug design strategies for the treatment of schizophrenia
Multi-target antipsychotics are essential for treating schizophrenia, resulting in better efficiency, fewer adverse effects, and improved patient compliance.
2020·14citations·Piotr Stępnicki et al.·Expert Opinion on Drug Discovery
Expert Opinion on Drug Discovery
Novel anilide and benzylamide derivatives of arylpiperazinylalkanoic acids as 5-HT1A/5-HT7 receptor antagonists and phosphodiesterase 4/7 inhibitors with procognitive and antidepressant activity.
Compound 22 shows promising procognitive and antidepressant properties, with stronger effects than escitalopram, offering a new perspective in the treatment of cognitive and depressive disorders.
2020·15citations·A. Jankowska et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Sustainable Synthesis of a Potent and Selective 5-HT7 Receptor Antagonist Using a Mechanochemical Approach
Mechanochemical reactions can efficiently synthesize PZ-1361, a potent 5-HT7 receptor antagonist with antidepressant properties in rodents, improving yield, reaction time, and reducing toxic solvent use.
2020·16citations·V. Canale et al.·The Journal of Organic Chemistry
The Journal of Organic Chemistry
Structure-activity relationships of serotonin 5-HT7 receptors ligands: A review.
New, potent, and selective 5-HT7 receptor ligands show potential for treating neuropsychiatric disorders like epilepsy and Alzheimer's disease, with potential therapeutic benefits in vivo studies.
2019·14citations·S. Thirumaran et al.·European journal of medicinal chemistry
European journal of medicinal chemistry
Novel antagonists of 5-HT6 and/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats
Novel 5-HT6 and 5-HT7 receptor antagonists enhance the antidepressant effects of escitalopram, reboxetine, and bupropion in rats, potentially aiding in treatment-resistant depression.
2019·8citations·A. Partyka et al.·Behavioural Brain Research
Behavioural Brain Research
Amino Acid Hot Spots of Halogen Bonding: A Combined Theoretical and Experimental Case Study of the 5-HT7 Receptor.
Halogen bonding hot spots identified in the 5-HT7 receptor can be used in rational drug design and optimization for any protein target.
2018·29citations·Rafał Kurczab et al.·Journal of medicinal chemistry
Journal of medicinal chemistry